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risk of intracranial haemorrhage. Bleeding can also occur spontaneously, after minor trauma or during surgical interventions. [1] [2] [3] Unlike haemophilia A and B, however, FXD occurs equally among both sexes and affected women and girls also experience menorrhagia. 2 In general, FX activity (FX:C) levels of 10-20 IU/dL are regarded as sufficient to maintain haemostasis, but some individuals may experience significant bleeding despite having FX:C levels above 20 IU/dL. 4, 5 Subjects with moderate FXD have levels of 1-5 IU/dL, and those with severe deficiency have levels <1 IU/dL. 2 As with other clotting factor disorders, the risk of bleeding increases with the severity of FX:C deficiency. 4 Until recently, treatment options for factor replacement to treat bleeds in FXD were restricted to fresh-frozen plasma (FFP) and prothrombin-complex concentrates (PCCs), which contain factors II, VII and IX, as well as FX. However, because none of these treatments are specific for FX, they can lead to inconsistent dosing and variable elevations in plasma levels of both FX and other coagulation factors. 6 Treatment with FFP requires high-volume doses, which can cause volume overload and anaphylaxis, while PCC carries a risk of thrombosis due to accumulation of the other factors contained in the concentrate. 1, 4, 7 Single-factor concentrates are therefore recommended to treat rare bleeding disorders where only 1 factor is deficient, such as FXD. The safety and efficacy of pdFX as short-term prophylactic and on-demand treatment for subjects ≥12 years old with moderate and severe FXD has been established, [11] [12] [13] but data in children <12 years are limited to 3 children who received pdFX on a compassionate use basis. This study was therefore conducted to investigate the efficacy, safety and pharmacokinetics of pdFX in the prophylactic and on-demand treatment of moderate or severe hereditary FXD in children <12 years.
| MATERIAL S AND ME THODS

| Study design and subject population
This open-label, multicentre, non-randomized, phase 3 prospective study (ClinicalTrials.gov, NCT01721681; EudraCT, 2012-003093-98)
was conducted between April 2015 and October 2016. The study was performed in accordance with the Declaration of Helsinki statement on ethical biomedical research and with the International Conference on Harmonisation Guidelines for Good Clinical Practice, 14 and the protocol was approved by a national independent ethics committee.
The parents or legal guardians of all subjects provided written informed consent prior to enrolment of the subject in the study; when appropriate, the subjects also provided written assent to participate.
Following the initial screening visit, subjects underwent a prophylactic treatment regimen with pdFX (administered intravenously at a maximum rate of 3 mL/min). 
| Subjects
Up to 12 subjects were enrolled to obtain a minimum of 8 evaluable subjects. Children aged <12 years were enrolled if they had a diagnosis of moderate or severe hereditary FXD based on basal plasma FX:C < 5 IU/dL on the lowest recorded FX:C assessment.
In addition, subjects were required to have either a history of severe bleeding or an F10 gene mutation known to cause a severe bleeding phenotype. Subjects were excluded from the study if they had a history of FX inhibitor development, thrombocytopenia or clinically significant renal or liver disease. The study protocol required at least 4 subjects in each age group (0-5 and 6-11 years)
and at least 4 with severe FXD. As some F10 mutations have been associated with more severe bleeding phenotypes, 15 designation as severe or moderate FXD included bleeding phenotype and F10
gene mutation in addition to plasma FX levels.
| Study endpoints
The primary endpoint was the efficacy of prophylactic pdFX treatment in reducing or preventing bleeding over 26 weeks (6 months).
Assessments were categorized as "excellent," "good," "poor" or "unassessable" and took into account the subject's risk of breakthrough bleeding (low/high risk), protocol compliance and attainment of trough FX:C levels ≥5 IU/dL (Table 1 ). Subjects at low risk for breakthrough bleeding were defined as those who received routine prophylaxis for ≥1 year prior to study entry, experienced ≤1 minor spontaneous bleeding episode (other than gum bleeds or bruising) requiring clinical assessment in the past year and experienced no major spontaneous bleeds in the past year; subjects at high risk for breakthrough bleeding were defined as those who did not meet criteria for low risk. 
| Statistical analyses
The primary and secondary endpoints were assessed using the perprotocol population, which was defined as all subjects who accumulated ≥50 exposure days and ≥26 weeks of treatment. Safety results
Efficacy rating Criteria
Excellent
No minor or major bleeds occurred during the study period or Lower frequency of bleeds than expected given subject's medical/treatment history Good Frequency of bleeds as expected given subject's medical/treatment history Poor Higher frequency of bleeds than expected given subject's medical/ treatment history or pdFX did not work at all
Unassessable
Subject did not complete 6 weeks of treatment with pdFX or Subject developed inhibitors to pdFX or Failure to meet the minimum trough level due to non-compliance with the dosing regimen pdFX, plasma-derived factor X.
TA B L E 1 Rating scale for investigator's overall assessment of pdFX efficacy in routine prophylaxis were summarized for the intent-to-treat/safety population, which included all subjects who received ≥1 dose of pdFX.
TA B L E 2 Baseline demographic and clinical characteristics (per-protocol population)
| RE SULTS
| Subject population
Nine subjects completed 11 treatment cycles, including 2 subjects who had 50 exposure days but were withdrawn erroneously from the study prior to completing 26 weeks of treatment. These 2 subjects were re-screened and completed a second, per-protocol treatment cycle. Only these subjects' results from the per-protocol treatment cycle were included in per-protocol analyses; results from both treatment cycles were merged for analyses using the intent-to-treat/safety population. Tables 2 and 3 summarize subject demographics, baseline characteristics and bleed history by age group. Eight subjects had severe FXD, and 1 subject had moderate FXD. Prior to study entry, 3 subjects had received pdFX for compassionate use. All subjects had been exposed to FX replacement therapy at enrolment and were receiving routine prophylactic treatment during the year prior to study entry; 8 subjects had been treated with other replacement factor concentrates, 5 had been treated with FFP and 2 had been treated with other blood products.
At study entry, all subjects were considered by the investigator to be at a low risk for bleeding, and no surgical interventions occurred during the study.
| Efficacy endpoints
In the per-protocol population, investigators rated the prophylactic efficacy of pdFX (primary endpoint) in all subjects as excellent.
Overall, 537 prophylactic infusions were administered in the per-protocol population (Table 4) During the study, 10 bleeds (6 minor, 3 major and 1 without severity recorded) were reported in 3 (33.3%) subjects in the per-protocol population, with a mean ± SD of 0.53 ± 0.34 bleeds per subject per month. The location, cause and severity of these bleeds are summarized in Table 5 . For 6 bleeds, duration was recorded and ranged Includes circumcision, umbilical stump bleed and cord bleed (1 bleed in 1 subject each); intracranial haemorrhage (1 bleed in each of 2 subjects); cord bleed and blood-streaked stool (2 bleeds in 1 subject); vomiting small amounts of blood and cord bleed (2 bleeds in 1 subject); and umbilical bleed and thigh haematoma and haematoma on back (2 bleeds in 1 subject).
pdFX (mean ± SD dose of 35.3 ± 7.2 IU/kg; range, 24.6-40.5 IU/kg).
In treating 2 of these major bleeds, both investigators and parents/ guardians rated pdFX efficacy as excellent; the third major bleed was neither treated nor assessed at the investigational site, and an error was not assessed either by the subject's parent/guardian. However, the investigator assessed the overall efficacy of pdFX for this patient as excellent.
In the per-protocol population, mean trough FX:C increased from 7.9 IU/dL at screening to 11.1 IU/dL at visit 5 (range of mean trough FX:C, 6.1-12.3 IU/dL; Table 6 ). All subjects maintained trough FX:C levels >5 IU/dL after visit 4. The mean 30-minute IR for the baseline and end-of-study visits combined was 1.74 IU/dL per IU/kg (Figure 1 ). IR was significantly lower at each time point among subjects aged 0-5 years compared with subjects aged 6-11 years (P < .05) (Figure 1 ).
| Safety
Across 665 exposure days in the safety population, a total of 28
AEs were reported in 8 (88.9%) of the study subjects, none of which were considered related to pdFX treatment ( Table 7 ). All reported AEs were of mild (26/28; 92.9%) or moderate (2/28; 7.1%) severity. One subject experienced 2 serious AEs (lower respiratory tract infection and influenza) requiring hospitalization; neither serious AE was considered related to pdFX treatment, and both resolved.
No deaths or other serious AEs were reported during the study.
No clinically significant changes were noted in vital signs, physical exams or laboratory measurements during the study, and no evidence of the FX inhibitor development was seen. Furthermore, no infusion site reactions were reported, regardless of administration route (central venous access device, n = 6; individual infusions, n = 3).
| D ISCUSS I ON
Several studies have been published on the use of pdFX in subjects ≥12 years old with hereditary FXD. [11] [12] [13] 16 However, data describing the use of FX-specific treatments in children <12 years old are scarce. Prior to the start of the current trial, 3 subjects had received pdFX as routine prophylaxis for 1-4 years on a compassionate use basis, but pharmacokinetic and efficacy data were not collected prospectively. Data published to date on use of other FX-containing products in children are minimal and inconclusive as to whether IR is affected by age. 7, 17, 18 In 1 study, routine prophylaxis with factor IX concentrate, which also includes some FX, in subjects with severe FXD (6 of whom were <20 years old) effectively controlled bleeding episodes. 19 However, as this was an evaluation of registry data, pharmacokinetic analyses were not included and potential variability in plasma levels of FX or other factors could not be assessed. The current trial was conducted to assess the efficacy and safety of pdFX in children <12 years when used prophylactically for 6 months and ≥50 exposure days.
Following 6 months of prophylactic treatment, investigators assessed the efficacy of pdFX in preventing or reducing bleeds as "excellent" for each of the 9 subjects, meaning that either the subject experienced no major or minor bleeds or that the frequency of bleeds was lower than expected given the subject's medical and treatment history. Of the 10 bleeds reported by 3 subjects, 3 were minor traumatic bleeds, 4 were menorrhagic bleeds and 3 were spontaneous nosebleeds, which are common in children even without bleeding disorders. One minor and 3 major bleeds in 2 subjects required treatment with pdFX, and in each case, the bleed was successfully treated with a single infusion. Of the 3 bleeds that were assessed for efficacy, pdFX treatment efficacy was rated as excellent. These results are consistent with a previous study conducted in subjects 
TA B L E 5 Characteristics of bleeding episodes (per-protocol population)
Subject number All bleeding episodes reported for subject 6 were nosebleeds. The 2 self-assessed major bleeds occurred following exercise.
c Subject 8 commenced menstrual bleeding shortly before the study and so the bleed frequency inevitably changed from the prestudy period.
d
Tranexamic acid was also administered.
e Site erroneously selected "Unassessable [pdFX given/not given another replacement factor given]" option on patient report form. Bleeds were treated at home and not assessed by the investigator site or subject; no other replacement factor was given.
aged ≥12 years in which pdFX successfully treated bleeds in 97% of subjects, and 83% of bleeds were treated with a single infusion. 12 In pharmacokinetic analyses, trough FX:C levels were maintained at >5 IU/dL for all subjects after the dose adjustment period.
Following a bolus dose of 50 IU/kg, the 30-minute IR remained consistent between the baseline and end-of-study visits (combined mean, 1.74 IU/dL per IU/kg for all subjects) but was significantly lower among younger subjects (1.53 IU/dL per IU/kg) compared with older subjects (1.91 IU/dL per IU/kg; P = .001). These differences in IR values are small but statistically significant and suggest that the pharmacokinetics of pdFX may differ for children <5 years old compared with older children.
Across 665 exposure days, no AEs occurred during this trial that were judged by investigators to be related to pdFX treatment. All reported AEs were mild or moderate in severity, and the 2 serious
AEs that occurred in 1 subject (mild influenza and moderate lower respiratory tract infection) resolved.
Although the development of neutralizing antibodies (ie, inhibitors) is a relatively common complication of clotting factor therapies, particularly for haemophilia A and (to a lesser extent) haemophilia B, 20, 21 inhibitors to FX have not been reported in hereditary FXD. 22, 23 During extended prophylactic use of pdFX in subjects who had previously received treatment with other clotting factors-including 3 subjects who had received pdFX for compassionate use prior to study entry-no evidence was seen in this study population for the development of FX inhibitors. These data are consistent with previous pdFX studies in patients ≥12 years old with moderate to severe TA B L E 6 Trough FX:C levels (IU/dL) at all study visits, by age group FXD, who also showed no sign of inhibitor development. 12, 13 In addition, no cases of FX inhibitor development have been reported in postmarketing safety surveillance.
Two limiting factors should be taken into account when interpreting the results of this study. First, not only is FXD a rare condition, but also this study focused on a relatively narrow age range. As a result, these results are limited by a small sample size (N = 9) and may or may not translate to patients' treatment responses in clinical practice. Caution should therefore be used when initiating a prophylactic treatment regimen with pdFX in children <12 years old-and particularly among children 0-5 years old-and patients should be monitored carefully for bleeds and to ensure that trough FX:C levels remain within the target range. In addition, studies have shown that inhibitors to clotting factors usually develop within the first 100 infusions, 24 but subjects in our study received a mean of 62 infusions.
Although most subjects had previously received treatment with pdFX or other clotting factors, the total accumulated number of infusions for each subject is unknown. The development of inhibitors is primarily associated with treatment of haemophilia A and B and, although rare, with treatment of deficiencies in coagulation factors V, VII, XI and XIII. 20, 21, 23 No known reports exist on the development of alloantibodies following replacement therapy for hereditary FXD, and a previous study of prophylactic treatment for up to 2 years reported no development of inhibitors. 12 However, it remains possible that long-term exposure to pdFX may lead to inhibitor development in some patients, and all individuals with FXD who receive pdFX on a prophylactic basis should be monitored for inhibitors.
| CON CLUS IONS
In this study in children aged <12 years with moderate to severe hereditary FXD, pdFX given as routine prophylaxis for 6 months was rated excellent at reducing or preventing bleeding episodes.
pdFX efficacy was also rated as excellent for on-demand treatment of both major and minor bleeds. Pharmacokinetic analysis demonstrated that at the range of doses and dosing intervals used in this study, trough levels were maintained above 5 IU/dL. However, 30-minute IR values were lower for children aged 0-5 years than for those aged 6-11 years, suggesting that the pharmacokinetics of pdFX may differ for the younger age group. Prophylactic dosing in children <12 years old should therefore be implemented cautiously and closely monitored to achieve the desired trough FX:C level.
In summary, consistent with previous findings in subjects aged ≥12 years, these results demonstrate that pdFX was well tolerated, safe and effective among subjects <12 years old.
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